All Stocks
pharma

BMY — Bristol-Myers Squibb Company

Conviction25
Congress 90d1
Insider 90d0
Markets0
Lobbying6
Contracts0
CountryUS

BMY

Bristol-Myers Squibb Company

pharma
25thin · 1 src1 source agree
📋 Lobbying

Congressional trades

Last 90 days
1 buy0 sell1 legislator
  • buy Mike Kelly · May 7, 2026

Prediction markets

No prediction markets reference this stock.

Lobbying filings

Last 2 years
  • CROSSROADS STRATEGIES, LLC · 2026 first_quarter
  • MARSHALL & POPP, LLC$40K · 2026 first_quarter
    PHA
  • CAPITOL COUNSEL LLC · 2026 first_quarter
    HCRMEDMMM
  • MARSHALL & POPP, LLC · 2026 first_quarter
    PHATRD
  • AVENUE SOLUTIONS · 2026 first_quarter
    HCRMMM
  • W STRATEGIES, LLC · 2026 first_quarter
    HCR

Country exposure

Domicile · not revenue geography

Approximated from company domicile — not revenue-by-geography.This panel maps the ticker to a single country using the company's registered domicile, a static lookup. It does not reflect where the company actually earns revenue or carries operational exposure (e.g. a US-domiciled chipmaker may have most of its real exposure in Taiwan or China).

🇺🇸 United States60/100
Posture: neutralView United States

Insider activity

No insider transactions filed in the last 90 days.

Federal contracts

No federal contract awards matched this company.

b5d1c9c